Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 13 04:00PM ET
0.4048
Dollar change
-0.0802
Percentage change
-16.54
%
Index- P/E- EPS (ttm)-1.56 Insider Own47.70% Shs Outstand41.75M Perf Week-49.32%
Market Cap16.90M Forward P/E- EPS next Y-0.53 Insider Trans0.00% Shs Float21.84M Perf Month-58.41%
Income-63.80M PEG- EPS next Q-0.18 Inst Own11.18% Short Float2.54% Perf Quarter-59.92%
Sales20.27M P/S0.83 EPS this Y53.13% Inst Trans-14.04% Short Ratio3.18 Perf Half Y-64.49%
Book/sh-0.27 P/B- EPS next Y56.67% ROA-85.73% Short Interest0.55M Perf Year-85.33%
Cash/sh0.64 P/C0.63 EPS next 5Y- ROE-362.79% 52W Range0.46 - 3.16 Perf YTD-86.18%
Dividend Est.- P/FCF- EPS past 5Y24.98% ROI- 52W High-87.19% Beta1.53
Dividend TTM- Quick Ratio3.23 Sales past 5Y25.00% Gross Margin76.47% 52W Low-11.05% ATR (14)0.07
Dividend Ex-DateMar 08, 2023 Current Ratio3.23 EPS Y/Y TTM57.93% Oper. Margin-329.46% RSI (14)10.10 Volatility17.72% 8.49%
Employees107 Debt/Eq- Sales Y/Y TTM90.67% Profit Margin-314.78% Recom2.20 Target Price4.67
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q42.52% Payout- Rel Volume3.32 Prev Close0.49
Sales Surprise-38.07% EPS Surprise1.59% Sales Q/Q-11.55% EarningsNov 07 BMO Avg Volume174.35K Price0.40
SMA20-47.98% SMA50-55.16% SMA200-68.86% Trades Volume579,633 Change-16.54%
Date Action Analyst Rating Change Price Target Change
Dec-12-24Downgrade Robert W. Baird Outperform → Neutral $10 → $1
Dec-10-24Downgrade BTIG Research Buy → Neutral
Apr-11-24Initiated BTIG Research Buy $6
Oct-03-23Initiated CapitalOne Overweight $10
Jul-06-23Initiated Evercore ISI Outperform $12
May-31-23Upgrade Jefferies Hold → Buy $0.60 → $7
May-24-23Initiated H.C. Wainwright Buy $10
Apr-14-23Initiated Robert W. Baird Outperform $10
Dec-09-24 08:30AM
Nov-27-24 07:30AM
Nov-17-24 07:30AM
Nov-08-24 07:30AM
Nov-07-24 07:30AM
09:05AM Loading…
Nov-05-24 09:05AM
Oct-30-24 04:30PM
Oct-04-24 09:05AM
Sep-10-24 07:30AM
Sep-03-24 07:30AM
Aug-13-24 12:00PM
Aug-08-24 09:00AM
07:30AM
Aug-06-24 07:30AM
07:30AM
07:30AM Loading…
Jul-01-24 07:30AM
Jun-28-24 07:39AM
Jun-27-24 04:30PM
Jun-26-24 06:53AM
Jun-25-24 07:30AM
07:30AM
Jun-13-24 04:30PM
May-30-24 07:30AM
May-16-24 07:30AM
May-09-24 01:54PM
08:35AM
07:30AM
May-08-24 07:30AM
May-06-24 07:30AM
May-02-24 10:01AM
07:30AM Loading…
07:30AM
Apr-24-24 05:05PM
Apr-22-24 04:35PM
Apr-04-24 09:55AM
Apr-03-24 07:00AM
Apr-01-24 01:53PM
08:35AM
07:00AM
Mar-21-24 05:00PM
Feb-28-24 07:30AM
Dec-21-23 07:00AM
Dec-14-23 07:00AM
Nov-28-23 07:00AM
Nov-22-23 07:30AM
Nov-09-23 07:30AM
Oct-31-23 09:25AM
Oct-25-23 09:11AM
Oct-12-23 02:52PM
Sep-05-23 08:30AM
Sep-01-23 08:30AM
Aug-24-23 08:30AM
Aug-23-23 09:55AM
Aug-13-23 08:07AM
Aug-10-23 07:30AM
Jul-19-23 06:34AM
Jun-28-23 08:30AM
Jun-26-23 08:30AM
Jun-14-23 08:30AM
Jun-08-23 01:11PM
Jun-05-23 07:30AM
May-30-23 04:30PM
May-11-23 07:30AM
May-08-23 04:30PM
May-05-23 04:30PM
Apr-14-23 12:51PM
Apr-06-23 04:30PM
Apr-04-23 08:30AM
Mar-20-23 02:04PM
Carisma Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of immunotherapies. It offers chimeric antigen receptor (CAR)-macrophages, a cell therapy platform focusing on the treatment of solid tumors. The company was founded by Michael Klichinsky and Saar Gill in April 2016 and is headquartered in Philadelphia, PA.